Selection pressure exerted by imatinib therapy leads to disparate outcomes of imatinib discontinuation trials

Abstract

Our analysis provides evidence for a mechanistic model of chronic myeloid leukemia selection by imatinib treatment and suggests that it may not be safe to discontinue therapy outside a clinical trial.